Clinical Trial: A Phase 1 Study of SGB-7342 in Subjects With Obesity or Overweight

U.S., Jan. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07324850) titled 'A Phase 1 Study of SGB-7342 in Subjects With Obesity or Overweight' on Dec. 23, 2025.

Brief Summary: The purpose of this study is to evaluate the safety and tolerability of subcutaneously administered SGB-7342 in adult subjects with obesity and overweight.

Study Start Date: Jan. 12

Study Type: INTERVENTIONAL

Condition: Obesity & Overweight

Intervention: DRUG: SGB-7342

SC injection, single dose

DRUG: SGB-7342-Matching placebo

Normal saline (0.9% NaCl) in a matching volume, SC injection, single dose

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Suzhou Sanegene Bio Inc.

Disclaimer: Curated by HT Syndication....